74 related articles for article (PubMed ID: 15844626)
1. Technology evaluation: cintredekin besudotox, NeoPharm/Nippon.
Rainov NG; Söling A
Curr Opin Mol Ther; 2005 Apr; 7(2):170-81. PubMed ID: 15844626
[TBL] [Abstract][Full Text] [Related]
2. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Kunwar S; Chang SM; Prados MD; Berger MS; Sampson JH; Croteau D; Sherman JW; Grahn AY; Shu VS; Dul JL; Husain SR; Joshi BH; Pedain C; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E15. PubMed ID: 16709020
[TBL] [Abstract][Full Text] [Related]
3. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Kunwar S; Prados MD; Chang SM; Berger MS; Lang FF; Piepmeier JM; Sampson JH; Ram Z; Gutin PH; Gibbons RD; Aldape KD; Croteau DJ; Sherman JW; Puri RK;
J Clin Oncol; 2007 Mar; 25(7):837-44. PubMed ID: 17327604
[TBL] [Abstract][Full Text] [Related]
4. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
5. hIL-13-PE38QQR. NeoPharm.
Barth S
Curr Opin Investig Drugs; 2001 Sep; 2(9):1309-13. PubMed ID: 11717820
[TBL] [Abstract][Full Text] [Related]
6. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.
Candolfi M; Xiong W; Yagiz K; Liu C; Muhammad AK; Puntel M; Foulad D; Zadmehr A; Ahlzadeh GE; Kroeger KM; Tesarfreund M; Lee S; Debinski W; Sareen D; Svendsen CN; Rodriguez R; Lowenstein PR; Castro MG
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20021-6. PubMed ID: 21030678
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-brain tumor cytotoxins specific for cancer cells.
Debinski W; Gibo DM; Obiri NI; Kealiher A; Puri RK
Nat Biotechnol; 1998 May; 16(5):449-53. PubMed ID: 9592393
[TBL] [Abstract][Full Text] [Related]
10. Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.
Rainov NG; Söling A
Curr Opin Mol Ther; 2005 Oct; 7(5):483-92. PubMed ID: 16248284
[TBL] [Abstract][Full Text] [Related]
11. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.
Kioi M; Takahashi S; Kawakami M; Kawakami K; Kreitman RJ; Puri RK
Cancer Res; 2005 Sep; 65(18):8388-96. PubMed ID: 16166317
[TBL] [Abstract][Full Text] [Related]
12. SGN-10. Seattle Genetics.
Smith SV
Curr Opin Investig Drugs; 2001 Sep; 2(9):1314-9. PubMed ID: 11717821
[TBL] [Abstract][Full Text] [Related]
13. [Development of a fusion toxin IL15M-PEdelta293 based on a receptor-specific IL-15 antagonist].
Niu YF; Zheng Y; Mao XH
Sheng Wu Gong Cheng Xue Bao; 2005 Jan; 21(1):42-6. PubMed ID: 15859327
[TBL] [Abstract][Full Text] [Related]
14. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Su Y; Ortiz J; Liu S; Bugge TH; Singh R; Leppla SH; Frankel AE
Cancer Res; 2007 Apr; 67(7):3329-36. PubMed ID: 17409442
[TBL] [Abstract][Full Text] [Related]
15. Technology evaluation: SB-485232, GlaxoSmithKline.
Golab J; Stoklosa T
Curr Opin Mol Ther; 2005 Feb; 7(1):85-93. PubMed ID: 15732534
[TBL] [Abstract][Full Text] [Related]
16. VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.
Biggers K; Scheinfeld N
Curr Opin Mol Ther; 2008 Apr; 10(2):176-86. PubMed ID: 18386230
[TBL] [Abstract][Full Text] [Related]
17. Technology evaluation: HspE7 (Stressgen).
Maciag PC; Paterson Y
Curr Opin Mol Ther; 2005 Jun; 7(3):256-63. PubMed ID: 15977424
[TBL] [Abstract][Full Text] [Related]
18. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases.
Joshi BH; Hogaboam C; Dover P; Husain SR; Puri RK
Vitam Horm; 2006; 74():479-504. PubMed ID: 17027527
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: LErafAON, NeoPharm.
Moreira JN; Simões S
Curr Opin Mol Ther; 2003 Oct; 5(5):547-52. PubMed ID: 14601525
[TBL] [Abstract][Full Text] [Related]
20. Technology evaluation: ING-1, XOMA.
Lewis LD
Curr Opin Mol Ther; 2003 Aug; 5(4):433-6. PubMed ID: 14513688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
